Weighted Average Number of Shares Outstanding, Basic of Apogee Therapeutics, Inc. from 30 Jun 2022 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Apogee Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2022 to 31 Dec 2025.
  • Apogee Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 60,690,820, a 10% increase year-over-year.
  • Apogee Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 60,690,820, a 10% increase from 2024.
  • Apogee Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 55,193,971, a 121% increase from 2023.
  • Apogee Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 25,005,774, a 916% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Apogee Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 60,690,820 +5,496,849 +10% 01 Oct 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q3 2025 58,773,731 +1,978,187 +3.5% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 58,428,344 +1,913,341 +3.4% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 58,195,272 +8,005,464 +16% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 55,193,971 +30,188,197 +121% 01 Oct 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q3 2024 56,795,544 +15,564,165 +38% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 56,515,003 +51,515,003 +1030% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 50,189,808 +45,189,808 +904% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 25,005,774 01 Oct 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
Q3 2023 41,231,379 +39,152,575 +1883% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 5,000,000 +3,750,000 +300% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 5,000,000 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q3 2022 2,078,804 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 1,250,000 01 Apr 2022 30 Jun 2022 10-Q 28 Aug 2023 2023 Q2

Apogee Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 60,690,820 +5,496,849 +10% 01 Jan 2025 31 Dec 2025 10-K 02 Mar 2026 2025 FY
2024 55,193,971 +30,188,197 +121% 01 Jan 2024 31 Dec 2024 10-K 02 Mar 2026 2025 FY
2023 25,005,774 +22,543,538 +916% 01 Jan 2023 31 Dec 2023 10-K 02 Mar 2026 2025 FY
2022 2,462,236 04 Feb 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.